<DOC>
<DOCNO>EP-0617618</DOCNO> 
<TEXT>
<INVENTION-TITLE>
ARYL-TRIFLATES AND RELATED COMPOUNDS.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3100	A61K3100	A61K3121	A61K31255	A61K3135	A61K3135	A61K31352	A61K31352	A61K3138	A61K3138	A61K31381	A61K31381	A61K31382	A61K31382	A61K3140	A61K3140	A61K31403	A61K31403	A61K31404	A61K31435	A61K31435	A61K314427	A61K314427	A61K31445	A61K31445	A61K31451	A61K31451	A61K31473	A61K31473	A61K31485	A61K31485	A61P2500	A61P2500	A61P2504	A61P2518	A61P2528	A61P4300	A61P4300	C07C30900	C07C30965	C07C30972	C07C30975	C07C30976	C07D20900	C07D20914	C07D20916	C07D21100	C07D21132	C07D21300	C07D21350	C07D22100	C07D22110	C07D22114	C07D22118	C07D22126	C07D22128	C07D22300	C07D22316	C07D24300	C07D24338	C07D27900	C07D27928	C07D30700	C07D30781	C07D31100	C07D31174	C07D33300	C07D33320	C07D33334	C07D33358	C07D33500	C07D33506	C07D40100	C07D40106	C07D40114	C07D45500	C07D45502	C07D47100	C07D47104	C07D48900	C07D48902	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61P	A61P	A61P	A61P	C07C	C07C	C07C	C07C	C07C	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61P25	A61P25	A61P25	A61P25	A61P25	A61P43	A61P43	C07C309	C07C309	C07C309	C07C309	C07C309	C07D209	C07D209	C07D209	C07D211	C07D211	C07D213	C07D213	C07D221	C07D221	C07D221	C07D221	C07D221	C07D221	C07D223	C07D223	C07D243	C07D243	C07D279	C07D279	C07D307	C07D307	C07D311	C07D311	C07D333	C07D333	C07D333	C07D333	C07D335	C07D335	C07D401	C07D401	C07D401	C07D455	C07D455	C07D471	C07D471	C07D489	C07D489	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Aryltriflates and related compounds having general formula (1) wherein Ar is an aromatic or heteroaromatic system of a compound which has a therapeutic, biological activity when it, in the same position, carries a hydroxy, alkyloxy, halo, ester or cyano group; wherein R1 is CF3, (C1-C8)alkyl, -CH2-(C3-C8)cycloalkylalkyl, substituted phenyl, substituted benzyl, substituted phenylethyl, substituted phenylpropyl, substituted 2-thiophenylethyl or substituted 2-thiophenylpropyl; possess both good pharmacodynamic and good pharmacokinetic properties and are thus useful drugs.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
LUNDBECK 
&
 CO AS H
</APPLICANT-NAME>
<APPLICANT-NAME>
H. LUNDBECK A/S
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
WIKSTROEM HAKAN
</INVENTOR-NAME>
<INVENTOR-NAME>
H. LUNDBECK A/S
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
ARYL-TRIFLATES AND RELATED COMPOUNDS.Field of the InventionThe present invention is directed toward new aryltriflates, and their pharmaceuti¬ cally acceptable salts, to processes for preparing such compounds, pharmaceutical preparations of such compounds and the use of such compounds in manufacture of a pharmaceutical preparation. Pharmaceutical preparations of these compounds are useful for peripheral and central nervous system disorders in mammals.Background of the InventionAryl triflates are used as intermediates in organic syntheses. They can thus be removed via reduction (NEt3+HCOO-) or substituted by other groups like CN and COOR (Oda, R., Kagaku (Kyoto) 1987, 42, 710-11 ; Cacchi, S. et al., Tetrahedron Lett 1986, 27, 5541-4; Chambers, M. R. I. et al., J. Chem. Soc, Perkin Trans 1989, 1, 1365-6; Kotsuki, H. et al., Synthesis 1990; Martorell, G. et al., Tetrahedron Lett1990, 31, 2357-60; Peterson, G. A. et al., Tetrahedron eft 1987, 28, 1381-4; Roth, G. P. et al., J. Org. Chem. 1991, 56, 3493-6; Saa, J. M. et al., J. Org. Chem. 1990, 55, 991-5; Subramanian, L R. et al., Synthesis 1984; Chambers, M. R. I. et al., J. Chem. Soc, Perkin Trans 1989, 1, 1365-6.; Takagi, K. et al., Bull. Chem. Soc. Jpn.1991 , 64, 1118-21 ; EP-A1 399982; Liu, Y. et a!., Bioorg. Med. Chem. Lett. 1991 , 1, 257-62.One aryltriflate with biological activity (5-HTTA affinity in a CNS preparation) is known ( EP-A1 399982; Liu, 1991 supra). In addition, the triflate of the analgetic substance paracetamol has been used as an intermediate in the conversion of the phenol into its cyano analogue (Chambers, 1989, supra; Takagi, 1991 , supra).Enzymatic deactivation of drugs (the Cytochrome P450 isoenzyme system) is a well known phenomenon, in particular phenols and methoxylated aryls are in general easily oxidized in the liver and elsewhere where these enzyme systems are active (e. g. the gastric mucosa and the lungs). Inactivation of phenols can take 

 place via direct conjugation (sulphation and glucoronidation) and/or via initial oxidation and then conjugation.Obviously, the inhibition of such enzymatic deactivation of drugs is highly desired, and the object of the present invention is to provide therapeutically effective drugs having a low liability for enzymatic deactivation. in particular drugs with better pharmacokinetic properties than the corresponding hydroxy and/or alkoxy substi¬ tuted analogues.It has now been found that triflate derivatives of drugs comprising a hydroxyaryl group or a similar group possess both good
</DESCRIPTION>
<CLAIMS>
WHAT IS CLAIMED:
1. An aryltriflate or a related compound having the general Formula 1 :
Formula 1 or pharmaceutically acceptable acid addition salts thereof, wherein
Ar is an aromatic or heteroaromatic system of a compound which has a therapeutic, biological activity when it, in the same position, carries a hydroxy, alkyloxy, halo, ester or cyano group; and
Ri is CF
3
, (CrCs) alkyl, -CH2-(C
3
-Cβ) cycloalkylalkyl, substituted phenyl, substi¬ tuted benzyl, substituted phenylethyl, substituted phenylpropyl, substituted 2-thio¬ phenylethyl or substituted 2-thiophenylpropyl; except the compounds wherein Ar is 2-(dipropylamino)-tetralin-8-yl or 4- acetamidophenyl.
2. A compound of claim 1 , Formula 1 , wherein Ri is CF
3
.
3. Compounds of claim 1 which are given in Enclosure 1 (at the end of this docu- ment).
4. A method for treating human disorders comprising the administration to a mammal of a therapeutic amount of a compound of Claim 1 or a pharmaceutically acceptable acid addition salt thereof to a patient in need thereof.
5. The method of claim 4, wherein said compound is administered in an amount of from about 1 to about 2000 mg oral daily dose, or from 0.1 to about 100 mg parenteral daily dose. 

</CLAIMS>
</TEXT>
</DOC>
